Preliminary research suggests the potential treatment blocks the novel coronavirus from replicating, which indicates the drug could slow the spread of the virus in patients, the New York-based drugmaker said.
Pfizer hopes to start clinical trials on the drug in August or September, according to the report.
The new drug candidate is one of several developments in the works for Pfizer to find a COVID-19 treatment.
Pfizer also is testing an approved rheumatoid-arthritis drug Xeljanz in Italy this week, researching if azithromycin works against the novel coronavirus, and working to develop a vaccine in partnership with German drugmaker BioNTech SE.
“I feel confident that we will win, battle by battle, to turn around this viral war against our society,” Mikael Dolsten, MD, PhD, Pfizer’s research and development chief, told The Wall Street Journal.
More articles on pharmacy:
Gilead boosts remdesivir production, now has 1.5M doses
Walgreens adds 6 COVID-19 safety measures to protect workers
2 East Coast pharmacy schools graduating students early to fight COVID-19
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.